Attention Deficit Hyperactivity Disorder - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights

• The Attention Deficit Hyperactivity Disorder (ADHD) market is anticipated to sustain a steady Compound Annual Growth Rate (CAGR) during the forecast period (2024-2034). This growth in market revenue is majorly propelled by advancements in emerging therapies, diagnostic techniques, heightened awareness of the condition, and a growing number of reported cases.
• The rise in ADHD cases is influenced by various factors, including genetic mutations, prenatal exposure to smoking or alcohol, low birth weight, and early childhood exposure to environmental toxins. Additionally, a family history of ADHD and brain injuries can heighten the risk of developing the condition.
• The ADHD market is highly competitive, featuring major players such as Tris Pharma with ONYDA XR and DYANAVEL XR, along with Supernus Pharmaceuticals’ QELBREE, among others. These established products define the landscape, underscoring the continuous innovation and rivalry within the industry.
• The future growth of the ADHD market is poised to be driven by companies like Cingulate’s CTx-1301, Otsuka Pharmaceutical’s Centanafadine, and Axsome Therapeutics’ SUNOSI (solriamfetol), which are advancing their assets through mid to late-stage development. With anticipated approvals of these therapies during the forecast period of 2024 to 2034, the overall ADHD therapeutic market is expected to experience a significant CAGR.
• Among the emerging therapies, Cingulate’s CTx-1301 is set to launch during the forecast period (2024-2034). In June 2024, the company completed manufacturing twelve registration batches of CTx-1301 in accordance with the US FDA requirements and has initiated NDA preparation, with submission anticipated in the first half of 2025.

The comprehensive report titled “Attention Deficit Hyperactivity Disorder - Market Insights, Epidemiology, and Market Forecast - 2034” offers a detailed analysis of ADHD. The report presents historical and projected epidemiological data covering total prevalent cases of ADHD, total diagnosed prevalent cases of ADHD, severity-specific diagnosed prevalent cases of ADHD, gender-specific diagnosed prevalent cases of ADHD, and age-specific diagnosed prevalent cases of ADHD. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements for ADHD. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Attention Deficit Hyperactivity Disorder Overview

ADHD is a common developmental disorder characterized by persistent inattention, hyperactivity, and impulsivity, which disrupt daily functioning and development. The exact causes of ADHD are unknown, but several risk factors have been identified, including genetics, exposure to lead during pregnancy or early childhood, alcohol and tobacco use during pregnancy, certain pregnancy-related factors, childhood head injuries, and parental mental health or family environment.

ADHD presents in three forms: predominantly inattentive, predominantly hyperactive-impulsive, and a combined type. Symptoms typically begin in childhood, impacting social relationships, school, or work performance, and continue into adulthood for many individuals. Key symptoms of ADHD include inattention, difficulty staying organized, hyperactivity such as restlessness or excessive talking, and impulsivity, including acting without considering consequences. These challenges are not due to defiance or a lack of comprehension.

Attention Deficit Hyperactivity Disorder Diagnosis and Treatment Algorithm

ADHD is diagnosed based on specific symptoms that begin before age 12 and persist for at least six months. Diagnosis involves three types: inattentive, hyperactive-impulsive, or combined. Children under 16 must display at least six symptoms, while adults and teens over 16 need five. Symptoms must occur in multiple settings and interfere with daily functioning. A thorough evaluation includes medical and mental health history, behavioral assessments, and psychological tests. Since other conditions like anxiety or depression can mimic ADHD symptoms, a comprehensive evaluation by a healthcare provider is essential to confirm the diagnosis.

ADHD is typically treated with a combination of behavior therapy and medication, with parent training being the first-line approach for preschool-aged children. Medications, including stimulants and nonstimulants, help manage symptoms like hyperactivity and impulsivity, though finding the right type and dose may take time. Behavioral interventions, such as cognitive behavioral therapy and social skills training, are also key to improving daily functioning. A healthy lifestyle, including proper nutrition, exercise, and sleep, further supports symptom management. Regular monitoring and tailored adjustments are essential to optimizing treatment.

Attention Deficit Hyperactivity Disorder Epidemiology

The epidemiology section of the ADHD market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of ADHD. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

During the ADHD analysis, it was observed that approximately 11.4% of US children aged 3-17 years have been diagnosed with ADHD.

It was noted that boys (14.5%) were more likely than girls (8.0%) to be diagnosed with ADHD, a trend consistent across both the 5-11 and 12-17 age groups.

It was found that among both boys and girls, the prevalence of ADHD was lower in children aged 5-11 years (8.6%) compared to those aged 12-17 years (14.3%).

The analysis revealed that more severe cases of ADHD in children, as reported by parents, were diagnosed earlier. The median age of diagnosis for severe ADHD was 4 years, while it was 6 years for moderate ADHD and 7 years for mild ADHD. Additionally, approximately one-third of children diagnosed with ADHD continue to retain the diagnosis into adulthood.

In 2016, the administrative prevalence of ADHD among children in Germany was estimated to be around 4.33%.

It was observed that the prevalence of ADHD in France is between 3.5% and 5.6%.

Overall, the pooled prevalence of ADHD in Italy was found to be approximately 2.9%, with a range of 1.1% to 16.7%.

The overall pooled prevalence of ADHD among children and adolescents in Spain was observed to be approximately 6.8%.

The National Institute for Health and Care Excellence estimates that the global prevalence of ADHD in children is around 5%, while in adults in the UK, it ranges from 3% to 4%.

In Japan, the estimated prevalence of adult ADHD was found to be approximately 1.65%.

The epidemiology of ADHD is expected to change during the forecast period (2024-2034).

Attention Deficit Hyperactivity Disorder Market Outlook

The ADHD therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period [2024-2034].

In May 2024, the US FDA approved ONYDA XR (clonidine hydrochloride), a once-daily extended-release oral suspension designed for night time dosing, for the treatment of ADHD. It can be used as either a monotherapy or as an adjunctive therapy alongside approved central nervous system (CNS) stimulant medications in pediatric patients aged six years and older.

In November 2021, the US FDA approved DYANAVEL XR (amphetamine), an extended-release once-daily tablet classified as CII, for the treatment of ADHD in patients aged 6 years and older.

In April 2021, the US FDA approved Qelbree (viloxazine extended-release capsules) for the treatment of ADHD in pediatric patients aged 6-17 years. Following this, in April 2022, the FDA expanded the indication for Qelbree to include the treatment of ADHD in adult patients aged 18 and older.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to the publisher, the ADHD market in the 7MM is expected to change significantly during the study period 2020-2034.

Attention Deficit Hyperactivity Disorder Drug Chapters

Marketed ADHD Drugs

ONYDA XR (clonidine hydrochloride): Tris Pharma

ONYDA XR is a centrally acting alpha2-adrenergic agonist approved for the treatment of ADHD in pediatric patients aged 6 years and older. It can be used either as a monotherapy or as an adjunctive treatment alongside central nervous system (CNS) stimulant medications, providing a versatile option for managing ADHD symptoms effectively. ONYDA XR is the first non-stimulant ADHD medication in Tris Pharma’s portfolio and holds the distinction of being the first and only liquid non-stimulant ADHD medication approved in the United States. Additionally, it is the only approved non-stimulant ADHD medication that offers nighttime dosing.

QELBREE (viloxazine extended-release capsules): Supernus Pharmaceuticals

QELBREE (viloxazine extended-release capsules) is a once-daily oral selective norepinephrine reuptake inhibitor indicated for the treatment of ADHD in adults and pediatric patients aged 6 years and older. Although the exact mechanism of action of viloxazine in managing ADHD is not fully understood, it is believed to work by inhibiting the reuptake of norepinephrine, thereby potentially enhancing neurotransmitter levels and improving attention and focus.

DYANAVEL XR (amphetamine): Tris Pharma

DYANAVEL XR is a prescription CNS stimulant indicated for the treatment of ADHD in patients aged 6 years and older. This liquid medication is administered orally and is designed for once-daily use. DYANAVEL XR (amphetamine) works by helping to increase attention and reduce impulsiveness and hyperactivity in individuals with ADHD, providing a beneficial therapeutic option for managing symptoms.

Emerging ADHD Drugs

The ADHD market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including Cingulate’s CTx-1301, Otsuka Pharmaceutical’s Centanafadine, and Axsome Therapeutics’ SUNOSI (solriamfetol), among others, have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.

CTx-1301: Cingulate

Cingulate’s lead candidate, CTx-1301, leverages its proprietary PTR platform to deliver a breakthrough multi-core formulation of dexmethylphenidate, an FDA-approved stimulant for ADHD. While stimulants are standard in ADHD treatment, maintaining full active-day coverage remains a challenge. CTx-1301 addresses this by offering three precise releases within a single tablet, ensuring rapid onset and sustained efficacy throughout the day, with the third dose activating when other extended-release products taper off.

In June 2024, Cingulate completed the manufacturing of twelve registration batches for CTx-1301 in line with FDA requirements and has begun NDA preparation, with submission expected in the first half of 2025. In August 2024, Cingulate secured a European patent for CTx-1301, further strengthening its global intellectual property position. In September 2024, the company initiated its final FDA-required study, a food effect study, expected to yield data by the end of the year.

Cingulate has also raised over USD 10 million in capital since mid-August 2024, with 58% sourced from its at-the-market facility, and achieved compliance with Nasdaq listing standards. This financial boost positions the company to focus on finalizing activities for NDA submission, targeting mid-2025. Initiating the final study marks a significant milestone, moving Cingulate closer to bringing CTx-1301 to market.

Centanafadine: Otsuka Pharmaceutical

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI) in development for the treatment of ADHD in children, adolescents, and adults. Originally developed by Neurovance, the drug was acquired by Otsuka Pharmaceutical in March 2017. In September 2023, Otsuka announced positive results from two six-week Phase III clinical trials, which assessed the efficacy, safety, and tolerability of centanafadine in treating ADHD in children and adolescents.

Solriamfetol: Axsome Therapeutics

Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, is approved to enhance wakefulness in adults experiencing excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) under the brand name SUNOSI. In vitro studies indicate that solriamfetol also exhibits agonist activity at TAAR1 and 5HT1a receptors. In July 2023, Axsome Therapeutics initiated dosing in the Phase III FOCUS trial, investigating solriamfetol as a potential treatment for ADHD in adults.

Attention Deficit Hyperactivity Disorder Market Segmentation

The ‘Attention Deficit Hyperactivity Disorder - Market Insights, Epidemiology, and Market Forecast - 2034’ report provides a detailed outlook of the current and future ADHD market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

ADHD Market Size by Countries

The ADHD market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2023, the United States held a significant share of the overall 7MM (Seven Major Markets) ADHD market, primarily attributed to the country’s higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Attention Deficit Hyperactivity Disorder Drugs Uptake

This section focuses on the sales uptake of potential ADHD drugs that have recently been launched or are anticipated to be launched in the ADHD market between 2020 and 2034. It estimates the market penetration of ADHD drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the ADHD market.

The emerging ADHD therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the ADHD market.

Attention Deficit Hyperactivity Disorder Market Access and Reimbursement

The ‘Attention Deficit Hyperactivity Disorder - Market Insights, Epidemiology, and Market Forecast - 2034’ report provides a descriptive overview of the market access and reimbursement scenario of ADHD.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current ADHD market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the ADHD domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or ADHD market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the ADHD unmet needs.

Attention Deficit Hyperactivity Disorder: KOL Insights

The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as Harvard Institute of Psychiatric Epidemiology and Genetics in the US, Carl von Ossietzky Universität Oldenburg in Germany, Université Paris Cité in France, European University of Rome in Italy, Hospital Universitari Vall d'Hebron in Spain, and University of Fukui in Japan, among others.
“Effective ADHD treatment combines medication and behavioral therapy, addressing symptoms like impulsivity and inattention. Personalization is key, requiring collaboration between patients, families, and healthcare professionals for optimal outcomes.”
“Despite progress in ADHD treatment, significant unmet needs persist due to stigma, limited awareness, and resource gaps. Underutilized support systems like family therapy and support groups further hinder comprehensive care. Addressing these issues is key to improving long-term outcomes for individuals with ADHD.”
“Diagnosing ADHD requires a thorough evaluation involving input from parents, teachers, and standardized assessments. Symptoms must appear before age 12, typically as inattention, hyperactivity, or impulsivity. Early identification is crucial for better outcomes.”

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the ADHD Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Attention Deficit Hyperactivity Disorder Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for ADHD. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging ADHD therapies.

Attention Deficit Hyperactivity Disorder Report Insights

• ADHD Patient Population
• Therapeutic Approaches
• ADHD Pipeline Analysis
• ADHD Market Size and Trends
• ADHD Market Opportunities
• Impact of Upcoming Therapies

Attention Deficit Hyperactivity Disorder Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• ADHD Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed ADHD Market
• ADHD Drugs Uptake

Attention Deficit Hyperactivity Disorder Report Assessment

• ADHD Current Treatment Practices
• Unmet Needs
• ADHD Pipeline Product Profiles
• ADHD Market Attractiveness

Key Questions

• How common is ADHD?
• What are the key findings of ADHD epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020-2034)?
• What are the currently available treatments for ADHD?
• What are the disease risk, burden, and unmet needs of ADHD?
• At what CAGR is the ADHD market and its epidemiology is expected to grow in the 7MM during the forecast period (2024-2034)?
• How would the unmet needs impact the ADHD market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of ADHD in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2024-2034)?
• How many companies are currently developing therapies for the treatment of ADHD?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the ADHD Market.
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.